WO2006013431A1 - Formulation pharmaceutique stable à libération régulée d’eletriptan - Google Patents

Formulation pharmaceutique stable à libération régulée d’eletriptan Download PDF

Info

Publication number
WO2006013431A1
WO2006013431A1 PCT/IB2005/002191 IB2005002191W WO2006013431A1 WO 2006013431 A1 WO2006013431 A1 WO 2006013431A1 IB 2005002191 W IB2005002191 W IB 2005002191W WO 2006013431 A1 WO2006013431 A1 WO 2006013431A1
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
pharmaceutical formulation
particles
release pharmaceutical
ammonio methacrylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002191
Other languages
English (en)
Inventor
Armin Knapp
Sven Schreder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Pfizer Inc
Original Assignee
Pfizer Ltd Great Britain
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0417042A external-priority patent/GB0417042D0/en
Application filed by Pfizer Ltd Great Britain, Pfizer Inc filed Critical Pfizer Ltd Great Britain
Publication of WO2006013431A1 publication Critical patent/WO2006013431A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Definitions

  • This application concerns a controlled release pharmaceutical formulation, in the form of a gelatine capsule, which shows improved stability.
  • This application further concerns a process for preparing such a formulation and a method for improving the storage stability of a gelatin encapsulated controlled release formulation.
  • the application relates to a controlled release pharmaceutical formulation in the form of a gelatine capsule comprising eletriptan, or a salt thereof, which shows improved stability, and the use of such a formulation in the treatment of migraine and in the prevention of migraine recurrence.
  • a controlled release of a drug is often achieved by coating a multiparticulate composition comprising the active compound (e.g. beads, pellets, granulates, mini-tablets, mini- or microcapsules or caplets) with a commercially available aqueous dispersion such as an ammonio methacrylate copolymer, particularly a Eudragit® copolymer manufactured by Rohm Pharma GmbH.
  • aqueous dispersion such as an ammonio methacrylate copolymer, particularly a Eudragit® copolymer manufactured by Rohm Pharma GmbH.
  • Such coated particulates are then usually dispensed into commercially available capsules, in most cases gelatine capsules, for ease of administration.
  • WO-A-02/09675 An example of such a gelatine-encapsulated controlled release formulation is described in WO-A-02/09675 in relation to the antimigraine drug eletriptan.
  • This patent application describes a a pharmaceutical composition in particulate form, suitable for oral administration, including a core containing eletriptan or a pharmaceutically acceptable salt thereof, the core being coated with a water-insoluble, permeable coating including one or more acrylic copolymer(s) containing trimethylammoniumethylmethacrylate groups, said composition being capable of achieving a sigmoidal pattern of controlled drug release.
  • the acrylic copolymer(s) is/are preferably selected from Eudragit RL® and Eudragit RS® and the particulate compositions described are preferably filled into hard gelatine capsules before administration.
  • such a controlled release formulation comprising a drug core coated with ammonio methacrylate copolymers, may be combined with a further portion of drug in immediate release form in the same capsule (see Example 7 of WO-A-02/09675).
  • multiparticulate compositions with different controlled release profiles may be combined in one capsule.
  • Such formulations are known as dual release formulations.
  • Such gelatine capsule preparations once prepared, are usually stored for a period of time before use.
  • the storage period may extend to months or even years and the conditions under which the preparations are stored may vary in terms of temperature and humidity.
  • the pattern of controlled release that an encapsulated preparation demonstrates when administered to a patient should not change during the storage period or the wrong dose of drug may be delivered to the patient at the wrong time.
  • gelatine capsule preparations manufactured in accordance with the teaching of WO-A-02/09675, containing a dual release formulation of eletriptan are not stable on storage, particularly under stressing conditions (i.e. relatively high temperature and/or humidity).
  • Such instability appears to be a general feature of gelatine capsules filled with multiparticulate compositions that are coated with aqueous dispersions of ammonio methacrylate copolymers such as Eudragit® RL 30 D (type A) or Eudragit® RS 30 D (type B) or with compositions that are produced from a solid ammonio methacrylate copolymer such as Eudragit® RL PO.
  • an isolating protective layer comprising a hydrophobic material, inserted between the ammonio methacrylate controlled release coating and the gelatine capsule.
  • the invention therefore provides a controlled release pharmaceutical formulation in the form of a gelatine capsule containing one or more particles, said particles comprising an anti-migraine drug and an ammonio methacrylate copolymer, characterised in that an isolating protective layer comprising a hydrophobic substance is inserted between the ammonio methacrylate copolymer and the gelatine capsule.
  • the isolating protective layer is coated onto the drug-containing particles. In another embodiment, the protective layer is coated onto the inside of the gelatine capsule.
  • the invention also provides a -multiparticulate composition, suitable for administration in a gelatine capsule, comprising an antimigraine drug-containing core, said core being coated with an inner controlled release coating and an outer isolating protective layer, wherein the inner coating comprises an ammonio methacrylate copolymer and the outer protective layer comprises a hydrophobic substance.
  • the invention further provides a method for improving the stability of a controlled release pharmaceutical formulation in the form of a gelatine capsule, said gelatine capsule containing one or more particles comprising an antimigraine drug and an ammonio methacrylate copolymer, by inserting an isolating protective layer comprising a hydrophobic substance between the ammonio methacrylate copolymer and the gelatine capsule.
  • the isolating protective layer comprises at least one hydrophobic substance.
  • the isolating protective layer may thus comprise one or more other substances in addition to a hydrophobic substance or may alternatively consist solely of one or more hydrophobic substances.
  • Hydrophobic in this context, means not soluble in water under acidic conditions, particularly at the pH of gastric juice which is normally from 1 to 3.
  • the hydrophobic substance will most commonly be a hydrophobic polymer. It may also be a hydrophilic polymer which has been rendered hydrophobic by the addition of one or more additives (e.g. a lipid or wax).
  • the hydrophobic substance may be a non-polymeric substance, such as a lipid or wax, which is capable of forming a continuous film around the drug-containing core.
  • Suitable hydrophobic polymers include a methacrylic acid-ethyl acrylate copolymer (e.g. a 1 :1 copolymer such as Eudragit® L), ethylcellulose (e.g. Aquacoat® ECD 30), a copolymer of methacrylic acid and polyvinyl-acetate-phthalate and a modified natural polymer having an anionic character (e.g. cellulose-acetate-phthalate and hydroxypropyl-cellulose-methyl-cellulose-phthalate or cellulose-acetate-trimellitate and hydroxypropyl-cellulose-methyl-cellulose-phthalate).
  • a methacrylic acid-ethyl acrylate copolymer e.g. a 1 :1 copolymer such as Eudragit® L
  • ethylcellulose e.g. Aquacoat® ECD 30
  • a copolymer of methacrylic acid and polyvinyl-acetate-phthalate and a modified natural polymer having an
  • lipids that are appropriate for rendering a hydrophilic polymer hydrophobic, are glycerol monostearate, stearic acid and a natural or synthetic wax or wax-like substance.
  • a typical isolating protective layer of this kind comprises Sepfilm LP 30 and 30% stearic acid.
  • Glycerol monostearate is an example of a non-polymeric hydrophobic substance which can be used according to the invention.
  • Hydrophobic polymers containing carboxylic and/or sulfonic acid groups are particularly preferred. Polymers containing these groups have a particularly strong protective effect.
  • a preferred isolating protective layer comprising a hydrophobic polymer is an enteric coating.
  • An enteric coating contains a polymer that is not soluble at acid pH (for instance, pH 1-3, as found in the stomach) but is soluble at neutral or alkaline pH (and therefore dissolves in the small intestine).
  • a preferred example of an enteric coating is a methacrylic acid-ethyl acrylate copolymer, especially a 1 :1 methacrylic acid-ethyl acrylate copolymer.
  • Such an enteric coating preferably additionally comprises an emulsifier such as sodium lauryl sulphate or polysorbate (most preferably about 2% by weight).
  • the level of enteric coating needed to achieve a protective effect in accordance with the present invention is relatively low in comparison to the level needed to achieve an effective enteric effect and a substantial retarding effect of the coating is thus avoided.
  • the isolating protective layer can therefore be relatively thin (5 to 50 ⁇ m, preferably 10 to 40 ⁇ m) in order to avoid undesired retarded release effects or other undesired influence on the controlled release profile of the capsule.
  • This cross-linking effect is responsible for release delays of up to 12 minutes, especially if the capsule contains immediate release components, while the standard disintegration time of a freshly prepared capsule is only about 3 minutes. Strongly cross-linked gelatin capsules may be even totally resistant to gastric juice. In less cross-linked preparations the release time of the pharmacologically active particulate components is still delayed by 5 to 10 minutes. In the case of pharmaceuticals such as analgesics or antimigraine agents, where a rapid onset of action is required, such a delay in disintegration time is clearly unacceptable. In the case of a dual release formulation, the longer disintegration time of the gelatine capsule seems to lead to unwanted, deleterious interactions between the particles programmed to have different release characteristics.
  • the capsule shell may partially leak relatively early e.g. as early as 3 minutes after being in contact with gastric juice, while maintaining its main structure and not allowing the release of particulate components for another 10 minutes before the complete breakup of the capsule-shell.
  • fast releasing components dissolve almost immediately inside the capsule-shell and form a highly concentrated solution of soluble ingredients which has sufficient time to interact with still intact slower releasing components.
  • Osmotic influences and different ion-size, ion-charge and ion-hydration of e.g. phosphate, citrate, methansulfonate, bromide or sulphate anions in comparison to e.g. chloride ions may cause severe damage to the controlled release layer of the slower releasing components, and these undesired interactions change the release characteristics of the slower releasing components, often to an unacceptable degree.
  • chloride anions from the ammonio methacrylate copolymers may exchange with sulphate anions from the immediate release portion of eletriptan hemisulphate, altering the properties of the controlled release coating and thus causing a significantly accelerated release of eletriptan from the controlled release particles.
  • chloride anions from the ammonio methacrylate copolymers may exchange with sulphate anions from the immediate release portion of eletriptan hemisulphate, altering the properties of the controlled release coating and thus causing a significantly accelerated release of eletriptan from the controlled release particles.
  • Such an interaction between chloride and sulphate anions takes place only if the capsule-shell is cross-linked and therefore hinders diffusion of sulphate anions from the immediate release portion out of the capsule during contact with gastric or intestinal juice.
  • the isolating protective layer provided by the present invention isolates volatile impurities, such as low molecular weight aldehydes, emanating from ammonio methacrylate copolymers that would otherwise trigger or initiate the cross- linking of the gelatine capsule shell.
  • the isolating protective layer can therefore alternatively be defined in functional terms as a layer (preferably a polymeric layer) which prevents the passage of volatile impurities such as low molecular weight aldehydes. It is also believed that the isolating protective layer provided by the present invention prevents, in the case of a dual release formulation, a rapid ingress of anions (e.g.
  • the isolating protective layer can therefore alternatively be defined in functional terms as a layer (preferably a polymeric layer) which significantly impedes the passage of anions (especially sulphate anions).
  • the invention therefore further provides a controlled release pharmaceutical formulation in the form of a gelatine capsule containing one or more particles, said particles comprising an antimigraine drug and an ammonio methacrylate copolymer, characterised in that the formulation is provided with means to prevent capsule crosslinking on storage.
  • the invention further provides a dual release pharmaceutical formulation in the form of a gelatine capsule containing immediate release and delayed release particles, said delayed release particles comprising an antimigraine drug and an ammonio methacrylate copolymer, characterised in that the delayed release particles are provided with means to prevent a significant amount of anion exchange in the ammonio methacrylate copolymer.
  • the amount of anion exchange is preferably less than 50%, more preferably less than 30%, most preferably less than 10%.
  • the level of volatile impurities in the formulation should be kept to a minimum.
  • the most important volatile impurities are thought to be aldehydes, especially lower aliphatic aldehydes with up to 6 carbon atoms, particularly formaldehyde and acetaldehyde.
  • the aldehyde content of the particles contained within the gelatine capsule should therefore preferably be less than 10 ppm, more preferably less than 5 ppm and most preferably less than 2 ppm.
  • the level of volatile aldehyde impurities may be reduced by vacuum treatment of the ammonio methacrylate-containing particles (e.g. at less than 100 mbar, preferably 1- 20 mbar), especially at raised temperatures (e.g. 25-50 0 C, preferably 35-45°C).
  • the particles may be exposed to a stream of clean and dry air or nitrogen at raised temperatures (30-50°C, preferably 35-45°C) in a fluidized bed unit.
  • the air or nitrogen should have a relative humidity of less than 20%.
  • a formulation according to the invention may also comprise, either as part of the isolating protective layer or otherwise, a quenching agent.
  • a quenching agent is a substance that is capable of chemically binding volatile impurities such as aldehydes.
  • Such a quenching agent may be an amine, protein, amino-acid, oligo- or polypeptide, especially gelatin and/or an amino-acid.
  • Particularly preferred quenching agents are cysteine, lysine, aspartic acid, asparagine, gelatine and glycine. Most preferred are glycine and aspartic acid.
  • the quenching agent is added to the isolating, protective layer.
  • the quenching agent may be separately applied, for example as a part of a separate layer around the particles.
  • This layer may also comprise a water soluble film forming material, for instance a hydrophilic polymer such as hydroxypropyl methylcellulose or hydroxypropyl cellulose.
  • the quenching agent will usually be present in an amount of from 1 % to 60% by weight. Hydroxypropyl methyl cellulose is particularly suitable since it is highly soluble in water and body liquids and exerts a minimal influence on the desired profile of drug release.
  • the quenching agent may be integrated into the ammonio methacrylate copolymer.
  • a quenching agent layer may be added in a conventional manner using, for example, the method described in US-A-2002/0034545, paragraphs [005] to [007], for compositions where an inner core is coated first with a retarding water-insoluble permeable or semipermeable coating including one or more acrylic copolymer(s) containing trimethyl-ammonium-metacrylate groups, whereafter the coated core is provided with a second water soluble coating layer comprising the quenching agent as described above, e.g. gelatin or an amino-acid.
  • gelatine capsule or gelatine capsule preparation refers to a capsule material with a gelatine content of about 20 to 100 weight %.
  • Capsule material containing less than 100% by weight gelatine comprise usual adjuvants known to a person skilled in the pharmaceutical capsule manufacturing art, such as water-soluble polymers.
  • the ammonio methacrylate copolymer is a type A or a type B ammonio-methacrylate copolymer (e.g. the products marketed under the trade-marks Eudragit RL and Eudragit RS) or a mixture of the two. These copolymers contain chloride counter-ions.
  • a particulate composition according to the invention may be coated with a so-called top-coat (see, for instance, WO-A-02/09675) which conventionally has a hydrophilic character, consisting, for example, of hydroxypropylmethylcellulose.
  • a top-coat which conventionally has a hydrophilic character, consisting, for example, of hydroxypropylmethylcellulose.
  • Such a top-coat may be inserted between the drug-containing core and the controlled release layer, between the controlled release layer and the layer comprising a hydrophobic substance or as an outer layer. More than one such top-coat may be used.
  • the ammonio raethacrylate coating applied to the particles of the invention may include one or more additional substances, such as a softening agent (e.g. an acetylated monoglyceride, triethyl citrate, acetyl-triethyl citrate, tributyl citrate, acetyltributyl citrate, another citrate ester, dibutyl phthalate, diethyl phthalate, another phthalate ester, diethyl sebacate, dibutyl sebacate, diethyl fumarate, diethyl succinate, a polyethylene glycol, glycerol, sesame oil, a lanolin alcohol or triacetin), an anti- tacking agent (e.g.
  • a softening agent e.g. an acetylated monoglyceride, triethyl citrate, acetyl-triethyl citrate, tributyl citrate, ace
  • talc calcium stearate, colloidal silicon dioxide, glycerin, magnesium-stearate, mineral oil, a polyethylene glycol, zinc- stearate, aluminium- stearate or glycerol-monostearate), a wetting agent (e.g.
  • sodium-lauryl-sulphate stearyl alcohol, acacia, benzalkonium chloride, cetomacrogol emulsifying wax, cetostearyl alcohol, cetyl alcohol, cholesterol, diethanolamine, sodium stearate, glycerol monostearate, hydroxypropyl-cellulose, a lanolin alcohol, triethanolamine, lecithin, poloxamer, a polyoxyethylene alkyl ether, a sorbitan ester, a stearyl alcohol or simethicone) or a water insoluble polymer (e.g. ethyl-cellulose, cellulose-acetate or a poly-methacrylate copolymer).
  • a preferred softening agent is triethyl-citrate, a preferred anti-tacking agent is talc and a preferred wetting agent is sodium-lauryl- sulphate.
  • any drug that is to be formulated with an ammonio methacrylate copolymer and contained in a gelatine capsule may benefit from the technology of the present invention whereby an isolating protective layer comprising a hydrophobic substance is inserted between the ammonio methacrylate copolymer and the gelatine capsule.
  • the drug is an antimigraine drug, particularly a
  • 5-HTIB 5-HTiD or 5-HTIF agonist.
  • Indole-containing antimigraine agents of the triptan class are particularly preferred. Examples are eletriptan, sumatriptan, naratriptan, zolmitriptan, rizatriptan, frovatriptan, alnatriptan, almotriptan and avitriptan and their pharmaceutically acceptable salts. Eletriptan, or a pharmaceutically acceptable salt thereof, is most preferred, being effective in the treatment of migraine and the prevention of migraine recurrence.
  • Preferred salts of eletriptan are the hydrobromide salt (especially the ⁇ -polymorph disclosed in WO-A-96/06842) and the hemisulphate salt (especially the form I polymorph disclosed in WO-A-01/23377). Eletriptan hemisulphate and its form I polymorph are particularly preferred.
  • eletriptan or a pharmaceutically acceptable salt thereof, is used according to the invention, it may be used alone or in combination with one or more further drugs, such as:
  • an opioid analgesic e.g. morphine, heroin, hydromorphone, oxymorphone, levorphanol, levallorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine or pentazocine;
  • NSAID nonsteroidal antiinflammatory drug
  • NSAID nonsteroidal antiinflammatory drug
  • diclofenac diflusinal, etodolac
  • fenbufen fenoprofen
  • flufenisal flurbiprofen
  • ibuprofen indomethacin
  • ketoprofen ketorolac
  • meclofenamic acid mefenamic acid
  • nabumetone naproxen
  • oxaprozin phenylbutazone
  • piroxicam sulindac, tolmetin or zomepirac
  • a barbiturate sedative e.g.
  • amobarbital amobarbital, aprobarbital, butabarbital, butabital, mephobarbital, metharbital, methohexital, pentobarbital, phenobartital, secobarbital, talbutal, theamylal or thiopental;
  • a benzodiazepine having a sedative action e.g. chlordiazepoxide, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam or triazolam;
  • an Hh antagonist having a sedative action e.g. diphenhydramine, pyrilamine, promethazine, chlorpheniramine or chlorcyclizine;
  • a sedative such as glutethimide, meprobamate, methaqualone or dichloralphenazone
  • a skeletal muscle relaxant e.g. baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol or orphrenadine;
  • an NMDA receptor antagonist e.g. dextromethorphan ((+)-3-hydroxy-N- methylmorphinan) or its metabolite dextrorphan ((+)-3-hydroxy-N- methylmorphinan), ketamine, memantine, pyrroloquinoline quinone or cis-4- (phosphonomethyl)-2-piperidinecarboxylic acid;
  • an alpha-adrenergic e.g. doxazosin, tamsulosin, clonidine or 4-amino-6,7- dimethoxy-2-(5-methanesulfonamido-1 ,2,3,4-tetrahydroisoquinol-2-yl)-5-(2- pyridyl) quinazoline;
  • a tricyclic antidepressant e.g. desipramine, imipramine, amytriptiline or nortriptiline;
  • an anticonvulsant e.g. carbamazepine or valproate
  • a tachykinin (NK) antagonist particularly an NK-3, NK-2 or NK-1 antagonist, e.g. ( ⁇ R,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5- (4-methylphenyl)-7H-[1 ,4]diazocino[2, 1 -g][1 ,7]naphthridine-6-13-dione (TAK- 637), 5-[[(2R,3S)-2-[(1 R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4- fluorophenyl)-4-morpholinyl]methyl]- ' i ,2-dihydro-3H-1 ,2,4-triazol-3-one (MK- 869), lanepitant, dapitant or 3-[[2-methoxy-5-
  • NK tachykinin
  • a muscarinic antagonist e.g oxybutin, tolterodine, propiverine, tropsium chloride or darifenacin;
  • a selective COX-2 inhibitor e.g. celecoxib, rofecoxib or valdecoxib;
  • a non-selective COX inhibitor preferably with Gl protection
  • nitroflurbiprofen HCT-1026
  • a coal-tar analgesic in particular paracetamol
  • a vanilloid receptor agonist e.g. resinferatoxin
  • antagonist e.g. capsazepine
  • beta-adrenergic such as propranolol
  • a PDEV inhibitor such as sildenafil, vardenafil, taladafil, 5-[2-ethoxy-5-(4- ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6- dihydro-7H-pyrazolo[4,3- ⁇ f
  • mGluRI metabotropic glutamate subtype 1 receptor
  • sertraline a serotonin reuptake inhibitor such as sertraline
  • a noradrenaline reuptake inhibitor especially a selective noradrenaline reuptake inhibitor such as (S,S)-reboxetine;
  • an inducible nitric oxide synthase (iNOS) inhibitor such as S-[2-[(1- iminoethyl)amino]ethyl]-2-methyl-L-cysteine or (2S,5Z)-2-amino-2-methyl-7-[(1 - iminoethyl)amino]-5-heptenoic acid;
  • iNOS inducible nitric oxide synthase
  • an acetylcholine esterase inhibitor such as donepezil
  • D2 dopamine type 2
  • an prostaglandin E 2 subtype 4 (EP4) antagonist such as ⁇ /-[( ⁇ 2-[4-(2-ethyl-4,6- dimethyl-1 H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl ⁇ amino)carbonyl]-4- methylbenzenesulfonamide or 4-[(1 S)-1 ⁇ ( ⁇ [5-chloro-2-(3-fluorophenoxy)pyridin-
  • a combination of eletriptan, or a pharmaceutically acceptable salt thereof, and an NSAID (such as naproxen, or a pharmaceutically acceptable salt thereof) or a selective COX-2 inhibitor (such as celecoxib, valdecoxib, rofecoxib or a pharmaceutically acceptable salt thereof) is particularly advantageous.
  • a non-limiting example of a typical capsule preparation according to the present invention is as follows:
  • the inner core composition contains an active compound in the form of crystals, granulates, pellets, spheric extrudates, spray dried products, minitablets, microcapsules or minicapsules in an amount of from 10 to 90% by weight.
  • This optional layer contains a hydrophilic polymer such as hydroxypropyl methylcellulose in an amount of from 1 to 20% by weight.
  • This layer controls the release of the active compound or compounds and preferably contains
  • a water-insoluble polymer such as an ammonio methacrylate-copolymer, type A and/ or B (or a mixture thereof) in an amount of from 10 to 50% by weight
  • a softening agent such as triethyl-citrate in an amount of from 1 to 15% by weight
  • a barrier coating containing at least one anti-tacking agent such as talc in an amount of from 3 to 50% by weight. 4.
  • This optional layer which is the same as layer (2) desribed above, contains a hydrophilic polymer such as hydroxypropyl methylcellulose in an amount of from 1 to 20% by weight.
  • This layer contains, for example,
  • an isolating protective polymer such as ethyl-cellulose (e.g. Aquacoat® ECD 30) or a methacrylic acid-ethyl acrylate copolymer (e.g. a 1 :1 copolymer such as Eudragit® L), in an amount of from 4 to 20% by weight,
  • a softening agent such as triethyl-citrate in an amount of from 0.25 to 4% by weight
  • an anti-tacking agent such as talc in an amount of from 1 to 15% by weight.
  • This optional layer contains for example gelatin, glycine, asparagine or cysteine in an amount of from 0.2 to 2% by weight.
  • This optional layer which is the same as layer (2) described above, is present in an amount of from 10 to 20% by weight.
  • quenching layer 6 may - as an additional or alternative layer - also follow layer 3.
  • Preparations according to the present invention may also contain only the isolating protective layer and no quenching layer. Instead of having a separate quenching protective layer, a quenching agent may be incorporated in the hydrophobic isolating protective layer or the outer barrier coating and thus form a bifunctional or multifunctional layer.
  • the preparation may also contain additional protective layers of both kinds and any practical number of top-coats or other useful layers known in the art.
  • the present invention thus provides a storage stable gelatin-capsule preparation which in a customary packaging may be stored over a long time even under the stressing conditions such as, for example, under relatively high temperatures of above
  • the invention is especially useful for capsule preparations for use in tropical regions.
  • the capsules of the invention maintain a dissolution profile that is substantially identical to the initial product before storage.
  • a dual release formulation comprising eletriptan hemisulphate immediate release beads and eletriptan hemisulphate controlled release beads in a gelatine capsule was prepared using the procedures of WO-A-02/09675.
  • Eletriptan hemisulphate starter cores were coated first with the Eudragit polymers to create the controlled release coating and then with hydroxypropyl methylcellulose (Opadry) as a topcoat.
  • the weight of the finished controlled release beads was 210.48mg.
  • the controlled release beads were cured in a tray oven at 4O 0 C for 24 hours and then filled together with immediate release beads into hard gelatine capsules (Size 1) using a Bosch GKF 400 capsule filling machine.
  • the capsule fill weight was 325.99mg.
  • the dissolution profile of a gelatine-encapsulated dual release formulation of eletriptan shows considerable variability when the formulation is stored in HDPE bottles under at least 2 different storage conditions (40°C/75% relative humidity and 30°C/60% relative humidity).
  • a further dual release- formulation comprising eletriptan hemisulphate immediate release beads and eletriptan hemisulphate controlled release beads in a gelatine capsule was prepared using the procedures of WO-A-02/09675.
  • Eletriptan hemisulphate starter cores were coated first with the Eudragit® polymers to create the controlled release coating and then with hydroxypropyl methylcellulose (Opadry) as a topcoat.
  • the weight of the finished beads was 175.40mg.
  • the controlled release beads were cured in a tray oven at 40°C for 24 hours and then filled together with immediate release beads into hard gelatin capsules (size 1) using a Bosch GKF 400 capsule filling machine.
  • the capsule fill weight was 280.94mg.
  • 3-month storage at 40°C/30% relative humidity in PVC/Aclar white opaque blisters 3-month storage at 25°C/60% relative humidity in HDPE bottles, 6-week storage at 40°C/30% relative humidity in HDPE bottle and 6-week storage at 30°C/60% relative humidity in HDPE bottles all resulted in significant changes to the release profile.
  • 02/09675 shows considerable variability when stored under different storage conditions (i.e. 25°C/60% relative humidity, 30°C/60% relative humidity, 40°C/30% relative humidity and 40°C/75% relative humidity) and in different packaging materials
  • Dual release gelatine capsules made according to Example 2 were tested for dissolution, as described in Example 2, and found to give the expected release profile. They were then stored at 40°C/75% relative humidity in PVC/Aclar White Opaque blisters and retested. The expected significant changes in dissolution profile were observed.
  • Minipress® retard 1 mg capsules containing prazosin hydrochloride, medium- chain triglycerides, lactose monohydrate, talc, maize starch, saccharose, ammonio methacrylate copolymer, indigo carmine (E 132), erythrosin (E127), iron oxides (E 172), and titanium dioxide (E 171) were stored for 6 weeks at 40°C/75% relative humidity in HDPE bottles.
  • the capsule shells were opened, emptied and filled with eletriptan immediate release beads (corresponding to 40 mg eletriptan) and eletriptan controlled release beads (corresponding to 40 mg eletriptan). A non-uniform release pattern of drug release was observed.
  • hard gelatine capsule shells (size 1) were filled with 282 mg of ammonio methacrylate copolymer Type A as a powder (Eudragit® RL PO) without any other ingredient.
  • the capsule shells were opened, emptied and filled with eletriptan immediate release beads (corresponding to 40 mg eletriptan) and eletriptan controlled release beads (corresponding to 40 mg eletriptan.
  • the capsule shells were closed again and subjected to a dissolution test. A non-uniform pattern of drug release was observed.
  • Eletriptan hemisulphate cores were prepared and coated with ammonio methacrylate copolymers Type A and B according to the disclosure of WO-A-02/09675.
  • a further coating of methacrylic acid-ethyl acrylate copolymer (Eudragit® L) was applied by dispersing 1 part of talc in 5 parts of purified water using an Ultra-Turrax® rotor-stator stirrer, dissolving triethylcitrate in a 30% aqueous dispersion of Eudragit® L (as Eudragit® L 30 D-55) using a blade stirrer, combining 6 parts of the aqueous talc dispersion and 7 parts of the aqueous Eudragit® L/triethyl citrate dispersion, stirring the combined dispersion using a blade stirrer and spraying onto the controlled release beads using a 6-inch Wurster coating device in a Glatt GPCG-1 fluid bed unit.
  • the coated controlled release beads were cured in a tray oven at 40°C for 24 hours and then filled together with immediate release beads into hard gelatine capsules (Size 1).
  • the capsule fill weight was 301.66mg.
  • Eudragit® L 30 D-55 is used as an enteric coating material to prevent the release of drugs in the stomach.
  • the coating level used in this Example is 5.4%, significantly lower than the level of Eudragit® L 30 D-55 recommended for enteric coating (10- 30%).
  • pH 2 acidic conditions
  • drug release is not prevented completely but the dissolution lag time is shifted upward by about 2 hours (from 9 to 11 h).
  • the dual release capsules were stored for 6 weeks at 40°C/75% relative humidity in induction-sealed HDPE bottles. No change of the dissolution profile was seen under this these conditions:
  • Eletriptan hemisulphate cores were prepared and coated with ammonio methacrylate copolymers Type A and B according to the procedures of WO 02/09675.
  • a further coating of Sepifilm LP 30 was applied using a 10% aqueous dispersion of Sepifilm LP 30 with 30% stearic acid at a final batch size of 1.3 kg in a Glatt GPCG-1 fluidized-bed unit with a 6-inch Wurster coating insert.
  • the bead weight was 174.90mg.
  • the controlled release beads were cured in a tray oven at 40 0 C for 24 hours and then filled together with immediate release beads into hard gelatine capsules Size 1.
  • the capsule fill weight was 291.86mg.
  • the capsule product proved to be stable (as judged by dissolution profile) for at least two weeks at 40°C/75% in induction-sealed HDPE bottles.
  • Eletriptan hemisulphate cores were prepared and coated with ammonio methacrylate copolymers Type A and B according to the procedures of WO-A-02/09675.
  • a further coating of ethylcellulose was applied by dissolving triethylcitrate in a 30% aqueous dispersion of ethylcellulose (Aquacoat® ECD 30) using a blade stirrer, diluting 5 parts of this dispersion with 1 part of purified water and spraying this final coating dispersion under continuous stirring with a blade stirrer onto the modified release beads using a Glatt GPCG-1 fluidized-bed unit with a 6-inch Wurster coating insert.
  • the final batch size was 1.5 kg.
  • the bead weight was 182.17mg.
  • the coated controlled release beads were cured in a tray oven at 4O 0 C for 24 hours and then filled together with immediate release beads into hard gelatine capsules (size 1).
  • the capsule fill weight was 299.13mg.
  • the dual release capsules were stored for 2 weeks at 40°C/75% relative humidity in induction-sealed HDPE bottles.
  • the dissolution profile proved to be stable under these storage conditions and no significant change in drug release profile was observed:
  • aqueous dispersion of talc was prepared using a rotor-stator stirrer (Ultra-Turrax®). Triethylcitrate was dissolved in purified water using a blade stirrer and 30% aqueous dispersions of ammonio methacrylate copolymer dispersions type A (Eudragit® RL) and B (Eudragit® RS) were added and dispersed.
  • aqueous talc dispersion and the aqueous ammonio methacrylate copolymer dispersion were combined and sprayed onto eletriptan hemisulphate starter cores using a Glatt GPCG-1 fluid-bed equipment with a 6-inch Wurster insert at a 1.3-kg batch size.
  • Glycine was dissolved in 1 part of water and triethylcitrate and talc were dispersed in another part of water using a rotor-stator stirrer (Ultra-Turrax®).
  • the glycine solution and the triethylcitrate/talc dispersion were added to two parts of a 30% aqueous dispersion of methacrylic acid-ethyl acrylate copolymer (Eudragit® L) and sieved through a sieve with 500 ⁇ m mesh size.
  • the combined dispersion was sprayed onto the controlled release beads using the same Wurster coating equipment at a temperature between 25 and 30 0 C.
  • the bead weight was 164.63mg.
  • the coated controlled release beads were cured in a tray oven at 40 0 C for 24 hours and then filled together with immediate release beads into hard gelatin capsules (size 1).
  • the capsule fill weight was 280.14mg.
  • Capsules were filled using a Bosch GKF 400 capsule filling machine with two pellet filling stations. Batch size was 5,245 capsules, machine speed 13,500 capsules/hour. Standard deviation of total fill weights was 0.8%.
  • hydrophobic isolating protective layer comprising methacrylic acid-ethyl acrylate copolymer in combination with glycine as a quenching agent prevents any deleterious interaction between ammonio methacrylate-containing controlled release beads and the gelatine capsule and provides a formulation which is stable upon storage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L’invention concerne une formulation pharmaceutique à libération régulée sous forme de capsule en gélatine comportant une ou plusieurs particules. Lesdites particules comprennent un antimigraineux et un copolymère méthacrylique ammoniacal, caractérisé par le fait qu’une couche de protection isolante comportant une substance hydrophobe est insérée entre le copolymère méthacrylique ammoniacal et la capsule en gélatine. Cette formulation a une stabilité accrue pendant le stockage.
PCT/IB2005/002191 2004-07-29 2005-07-21 Formulation pharmaceutique stable à libération régulée d’eletriptan Ceased WO2006013431A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0417042.9 2004-07-29
GB0417042A GB0417042D0 (en) 2004-07-29 2004-07-29 Stable pharmaceutical formulation
US60238904P 2004-08-17 2004-08-17
US60/602,389 2004-08-17

Publications (1)

Publication Number Publication Date
WO2006013431A1 true WO2006013431A1 (fr) 2006-02-09

Family

ID=35064592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002191 Ceased WO2006013431A1 (fr) 2004-07-29 2005-07-21 Formulation pharmaceutique stable à libération régulée d’eletriptan

Country Status (1)

Country Link
WO (1) WO2006013431A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009675A1 (fr) * 2000-08-02 2002-02-07 Pfizer Limited Composition particulaire d'eletriptan presentant un modele sigmoide de liberation commandee
US20020058050A1 (en) * 1993-11-23 2002-05-16 Richard S. Sackler Treating pain by administering 24 hours opioid formulations exhibiting rapid rise of drug level
US20020182253A1 (en) * 1995-12-22 2002-12-05 Laboratoires Des Produits Ethiques Ethypharm Sustained-release microgranules containing diltiazem as active principle
US20030198673A1 (en) * 1992-01-27 2003-10-23 Benjamin Oshlack Controlled release formulations coated with aqueous dispersions of acrylic polymers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198673A1 (en) * 1992-01-27 2003-10-23 Benjamin Oshlack Controlled release formulations coated with aqueous dispersions of acrylic polymers
US20020058050A1 (en) * 1993-11-23 2002-05-16 Richard S. Sackler Treating pain by administering 24 hours opioid formulations exhibiting rapid rise of drug level
US20020182253A1 (en) * 1995-12-22 2002-12-05 Laboratoires Des Produits Ethiques Ethypharm Sustained-release microgranules containing diltiazem as active principle
WO2002009675A1 (fr) * 2000-08-02 2002-02-07 Pfizer Limited Composition particulaire d'eletriptan presentant un modele sigmoide de liberation commandee

Similar Documents

Publication Publication Date Title
KR0140492B1 (ko) 방출억제성 오피오이드 제형
JP4790415B2 (ja) 医薬組成物
JP5186100B2 (ja) 制御／調整放出型メチルフェニデート経口製剤
CA2306333C (fr) Formulation multiparticulaire de morphine orale
JP5628480B2 (ja) 医薬成分を含有するコーティングカプセル
CA2211284C (fr) Forme posologique a unites multiples et a liberation prolongee
FI119141B (fi) Menetelmä farmaseuttisen formulaation valmistamiseksi
DK2596784T3 (en) Tapentadol compositions
JP4286452B2 (ja) 胃において保護されるオメプラゾール微粒子、その製造方法および医薬製剤
WO2005092336A1 (fr) Préparation de lessivage maîtrisé et procédé de fabrication de ladite préparation
CZ321795A3 (en) Pharmaceutical preparation and process for preparing thereof
EP1330238A1 (fr) Formulations pharmaceutiques contenant un medicament anti-inflammatoire non steroidien et un inhibiteur de la pompe a protons
EP2352494A1 (fr) Nouvelles formes galéniques puissantes du tapentadol
JP2007510676A (ja) 作用物質放出に関して調節作用のある物質を含有する、多層の剤形
IE871106L (en) Pharmaceutical formulation for oral use.
RS50407B (sr) Oralne formulacije opijatnog agonista otporne na mehaničke,termičke i/ili hemijske promene fizičkih osobina doznog oblika
WO1992020326A1 (fr) Composition multicouche a liberation regulee
CA3077514C (fr) Comprimes de deferiprone a liberation retardee et procedes d'utilisation correspondants
US20220313699A1 (en) Compositions for delivery of reboxetine
US20160074333A1 (en) Pharmaceutical compositions of tamsulosin or salts thereof
AU2012345659B2 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2005526739A (ja) コレステロール濃度を低下させる活性成分を含み、活性成分が遅延放出される薬剤
US20050053651A1 (en) Stable pharmaceutical formulation
WO2006013431A1 (fr) Formulation pharmaceutique stable à libération régulée d’eletriptan
CN107820424B (zh) Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase